A Review: Gene Therapy for Inherited Retinal Diseases: Clinical Advances, Regulatory Milestones, and Emerging Therapeutic Frontiers
IFR Journal of Medicine and Surgery · 18.07.2025 · 2 (3) · 30-38
DOI: 10.70146/msv02i03.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift IFR Journal of Medicine and Surgery, erschienen am 18.07.2025. Verfasst von Mirza Mohammed Ismail Baig und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Inherited retinal diseases (IRDs) are a genetically heterogeneous group of progressive disorders and a leading cause of visual impairment worldwide. Advances in molecular genetics and vector engineering have enabled the development of targeted gene therapies, culminating in the clinical approval of voretigene neparvovec-rzyl for RPE65-associated retinal dystrophy.
Methods
This review critically evaluates published literature and clinical trial data on gene therapy approaches for IRDs, including gene augmentation, genome editing, and RNA-based modulation. Delivery strategies, vector platforms, regulatory frameworks, and ethical implications are also examined to provide a comprehensive overview of the current landscape and future directions.
Results
Approved and investigational therapies demonstrate encouraging outcomes in restoring or stabilizing visual function across a spectrum of IRDs. The clinical pipeline includes AAV-based therapies targeting RPGR, CHM, and RS1, with evolving approaches such as dual-vector delivery, CRISPR/Cas9 gene editing, and antisense oligonucleotide therapy. Challenges related to immunogenicity, vector capacity, manufacturing scale-up, and equitable access remain prominent.
Conclusion
Gene therapy for IRDs has entered a pivotal phase of clinical translation. While technological innovation continues to broaden therapeutic reach, long-term success will depend on overcoming logistical, regulatory, and ethical barriers. Future efforts should emphasize scalable delivery, global accessibility, and mutation-specific personalization to achieve meaningful impact in patient care.
Zitieren
APA
Baig, M. M. I., Aowang, Q., Ruxu, S., Ningyu, W., Ziyun, J., Ziyu, Z., Subair, J., & Weiwei, Z. (2025). A Review: Gene Therapy for Inherited Retinal Diseases: Clinical Advances, Regulatory Milestones, and Emerging Therapeutic Frontiers. IFR Journal of Medicine and Surgery, 2(3), 30-38. https://doi.org/10.70146/msv02i03.005
Vancouver
Baig MMI, Aowang Q, Ruxu S, Ningyu W, Ziyun J, Ziyu Z, et al. A Review: Gene Therapy for Inherited Retinal Diseases: Clinical Advances, Regulatory Milestones, and Emerging Therapeutic Frontiers. IFR Journal of Medicine and Surgery. 2025;2(3):30-38. doi:10.70146/msv02i03.005
BibTeX
@article{Baig2025,
author = {Baig, Mirza Mohammed Ismail and Aowang, Qiu and Ruxu, Sun and Ningyu, Wang and Ziyun, Jiao and Ziyu, Zhu and Subair, Jassim and Weiwei, Zhang},
title = {A Review: Gene Therapy for Inherited Retinal Diseases: Clinical Advances, Regulatory Milestones, and Emerging Therapeutic Frontiers},
journal = {IFR Journal of Medicine and Surgery},
year = {2025},
volume = {2},
number = {3},
pages = {30--38},
doi = {10.70146/msv02i03.005}
}
EUVIMED